Heron Therapeutics, INC /DE/ Form 4 insider transactions

CEO Craig Collard reports the vesting of restricted stock units into Heron Therapeutics common stock.

CEO Craig Collard reports the vesting of restricted stock units and acquisition of common stock.

Director Michael Kaseta reports acquisition of Heron Therapeutics stock and options in a Form 4/A filing with the SEC.

A director at Heron Therapeutics has been granted a significant number of stock options and restricted stock units, according to a recent SEC filing.

Director Sharmila Dissanaike acquired stock options and restricted stock units in Heron Therapeutics, Inc.

Director Craig A. Johnson reports acquisition of restricted stock units and stock options in Heron Therapeutics.

Director Susan Rodriguez reports acquisition of Heron Therapeutics stock and options via grant.

Director Christian Waage of Heron Therapeutics received stock options and restricted stock units on January 31, 2025, according to a Form 4/A filing with the SEC.

William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, acquired stock options and restricted stock units on January 31, 2025.

EVP and CFO of Heron Therapeutics, Ira Duarte, reports the acquisition of stock options and restricted stock units.

CEO Craig Collard reports acquisition of stock options and restricted stock units in Heron Therapeutics, Inc.

Director Michael Kaseta of Heron Therapeutics acquired 17,950 shares of common stock and 35,900 stock options on January 30, 2025.

Director Sharmila Dissanaike acquired 17,950 restricted stock units and 35,900 stock options in Heron Therapeutics, according to a recent SEC filing.

Director Craig Johnson of Heron Therapeutics acquired 17,950 restricted stock units and 35,900 stock options on January 30, 2025.

Director Susan Rodriguez of Heron Therapeutics acquired 17,950 shares of common stock and 35,900 stock options on January 30, 2025.

Director Christian Waage of Heron Therapeutics acquired 17,950 shares of common stock and 35,900 stock options on January 30, 2025.

Director Adam Morgan of Heron Therapeutics reported the acquisition of restricted stock units and stock options, along with indirect ownership of a large block of common stock through Velan Capital Master Fund LP.

EVP and Chief Financial Officer of Heron Therapeutics, Ira Duarte, reports the acquisition of 3,874 shares of common stock and 3,874 restricted stock units on January 19, 2025.

William P. Forbes, EVP and Chief Development Officer at Heron Therapeutics, exercised stock options and increased his holdings of common stock.

Heron Therapeutics CEO, Craig Collard, acquired 13,797 shares of common stock through the vesting of restricted stock units on January 19, 2025.

Director Michael Kaseta reports acquisition and disposal of Heron Therapeutics stock and stock options.

Ira Duarte, EVP and CFO of Heron Therapeutics, reports the vesting of restricted stock units into common stock.

William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, exercised stock options and reported changes in beneficial ownership.

CEO Craig Collard reported the vesting of restricted stock units and subsequent acquisition of common stock.

CEO Craig Collard reports the vesting of restricted stock units into common stock.

William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, exercised stock options and acquired 3,875 shares of common stock on July 19, 2024.

Ira Duarte, EVP and CFO of Heron Therapeutics, reports the vesting of restricted stock units and subsequent acquisition of common stock on July 19, 2024.

EVP and Chief Financial Officer of Heron Therapeutics, Ira Duarte, reports the acquisition of 12,500 shares of common stock through the vesting of restricted stock units.

William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, exercised stock options, acquiring 12,500 shares of common stock on June 6, 2024.

Ira Duarte, EVP and CFO of Heron Therapeutics, reports the vesting of restricted stock units and subsequent disposition of shares to cover tax obligations.